LIFE SCIENCES
Drug Regulation in all the Wrong Places
The FDA’s myopic focus on early-stage testing and lack of emphasis on phase four human clinical trials has led to many safety-related drug recalls in recent years, meriting a reexamination of our regulatory system.







